IGM Biosciences (IGMS)
(Delayed Data from NSDQ)
$1.31 USD
+0.04 (3.15%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $1.31 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IGMS 1.31 +0.04(3.15%)
Will IGMS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IGMS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IGMS
IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates
IGMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates
Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates
BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Other News for IGMS
IGM Biosciences (IGMS) Shares Surge After Acquisition Announcement
IGM Biosciences climbs on merger deal with Concentra
IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1. ...
IGM Biosciences be acquired by Concentra for $1.247 in cash per share
IGM Biosciences moved to No Rating at BofA